Sa1354 HELICOBACTER PYLORI TREATMENT REDUCES THE RISK OF GASTRIC CANCER FOR HIGH GENETIC RISK POPULATIONS: A LONGITUDINAL STUDY
Leggi →
Maggio 2024
Risultati per: Trattamento dell'infezione da Helicobacter Pylori
Questo è quello che abbiamo trovato per te
Sa1353 INFLUENCE OF H. PYLORI TREATMENT ON METACHRONOUS RECURRENCE IN ELDERLY PATIENTS AFTER ENDOSCOPIC RESECTION OF GASTRIC CANCER: A NATIONWIDE COHORT STUDY
Leggi →
Maggio 2024
Sa1360 HELICOBACTER PYLORI DIAGNOSTIC TESTS AND INDICATIONS OF TREATMENT FROM THE LATIN AMERICAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-LATAMREG).
Leggi →
Maggio 2024
Sa1351 INSIGHTS INTO THE EPIDEMIOLOGY AND DETERMINANTS OF HELICOBACTER PYLORI-NEGATIVE GASTRITIS: A COMPREHENSIVE ANALYSIS
Leggi →
Maggio 2024
Sa1350 INHIBITION OF THE INNATE IMMUNE RESPONSE BY H.PYLORI
Leggi →
Maggio 2024
Sa1369 UPPER GASTROINTESTINAL ENDOSCOPY COMBINED WITH GASTRIC JUICE ANALYSIS BY THE MEDICAL DEVICE ENDOFASTER FOR REAL-TIME ASSESSMENT OF H. PYLORI INFECTION AND MOLECULAR-BASED ANTIBIOTIC RESISTANCE
Leggi →
Maggio 2024
Sa1376 EFFICACY OF PROBIOTICS REGIMENS FOR HELICOBACTER ERADICATION: A SYSTEMATIC REVIEW, PAIR-WISE AND NETWORK META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Leggi →
Maggio 2024
Sa1375 EPIDEMIOLOGY AND ANTIBIOTIC RESISTANCE PATTERN OF HELICOBACTER PYLORI INFECTION IN SOUTH EAST ASIA COUNTRIES: A SYSTEMATIC REVIEW WITH META-ANALYSIS
Leggi →
Maggio 2024
Sa1374 THE IMPACT OF DIRECT MESSAGING OF H. PYLORI ANTIMICROBIAL SUSCEPTIBILITY TESTING RESULTS ON ENDOSCOPISTS’ PRESCRIPTION OF APPROPRIATE TREATMENT
Leggi →
Maggio 2024
Sa1373 EXCELLENT ERADICATION RATE OF ONCE-DAILY VONOPRAZAN LEVOFLOXACIN-BASED QUADRUPLE THERAPY FOR H. PYLORI INFECTION IN HIGH CLARITHROMYCIN RESISTANCE AREA: A PROSPECTIVE RANDOMIZED STUDY (ONCE-VONO TRIAL)
Leggi →
Maggio 2024
Sa1372 COMPARISON OF THE EFFICACY AND SAFETY OF DUAL AND QUADRUPLE THERAPY WITH ILAPRAZOLE IN THE ERADICATION OF H.PYLORI
Leggi →
Maggio 2024
Sa1371 REAL-WORLD EFFICACY OF SECOND-LINE THERAPIES FOR HELICOBACTER PYLORI: A POPULATION-BASED STUDY
Leggi →
Maggio 2024
Sa1370 INCIDENCE AND PREDICTORS OF C. DIFFICILE INFECTION AFTER HELICOBACTER PYLORI TREATMENT IN A LARGE, COMMUNITY-BASED U.S. POPULATION
Leggi →
Maggio 2024
Sa1361 CROSS-SECTIONAL ANALYSIS OF REAL-WORLD DATA IN GASTRIC CANCER SCREENING BASED ON HELICOBACTER PYLORI INFECTION HISTORY IN PRIVATE HEALTH CHECK-UPS
Leggi →
Maggio 2024
Sa1368 SYNERGISTIC EFFECTS OF NOVEL PENICILLIN-BINDING PROTEIN 1A AMINO ACID SUBSTITUTIONS CONTRIBUTE TO HIGH-LEVEL AMOXICILLIN RESISTANCE OF HELICOBACTER PYLORI
Leggi →
Maggio 2024
Sa1367 BOTH 14-DAY VONOPRAZAN TRIPLE THERAPY AND 14-DAY RABEPRAZOLE REVERSE HYBRID THERAPY ARE SUPERIOR TO 14-DAY VONOPRAZAN HIGH-DOSE DUAL THERAPY FOR THE FIRST-LINE ANTI-H. PYLORI TREATMENT IN POPULATION WITH HIGH RATES OF ANTIBIOTIC RESISTANCE
Leggi →
Maggio 2024
